Adjuvant chemotherapy of gastric cancer: which regimens?
Gastric cancer is still a major health problem and a leading cause of cancer mortality despite a worldwide decline in incidence. Surgical resection with curative potential is the only treatment modality of scientific proven effectiveness. Many phase III trials of adjuvant therapy have been conducted, however, postoperative treatment modalities have not proven to be superior to pos-surgical observation alone. Therefore, at present the routine use of adjuvant therapy should be regarded as an investigational approach. Improved clinical trial designs with standardized surgical techniques and the incorporation of newer active drugs are needed.
De Vita
F
F
Division of Medical Oncology, F. Magrassi & A. Lanzara Department of Clinical and Experimental Medicine, Second University of Naples, School of Medicine, Naples, Italy. fernandodevita@yahoo.it
Orditura
M
M
Ciardiello
F
F
Catalano
G
G
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D013274:Stomach Neoplasms / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors; D002945:Cisplatin